We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:21-30 of 59

REVATIO patent ruled invalid for lack of sound prediction and obviousness
  • Stikeman Elliott LLP
  • Canada
  • June 18 2010

In an application under the Patented Medicines (Notice of Compliance) Regulations (“Regulations”), Pfizer sought an order prohibiting the Minister of Health (“Minister”) from issuing a notice of compliance (“NOC”) to Ratiopharm for a generic version of the drug REVATIO (containing the medicine sildenafil citrate (“sildenafil”) the same medicinal ingredient contained in VIAGRA) until after the expiry of the 324 patent.


Bifurcation order not appropriate in action involving patent infringement and breach of Competition Act
  • Stikeman Elliott LLP
  • Canada
  • June 9 2010

The plaintiff, Garford, appealed from an order of a prothonotary allowing bifurcation (separate trials) of the issue of liability from the issues of damages or accounting of profits in an action alleging patent infringement and breach of the Competition Act.


Lehigh Cement: more uncertainty surrounding GAAR
  • Stikeman Elliott LLP
  • Canada
  • June 2 2010

On May 17, 2010, the Federal Court of Appeal (FCA) released its decision in the case of Lehigh Cement Limited v. R.


Court disallows expert disbursements in patent case
  • Stikeman Elliott LLP
  • Canada
  • May 26 2010

Counsel should be prudent in determining when it is appropriate to retain experts and have them incur costs on your client's behalf.


Toronto releases revised draft zoning by-law
  • Stikeman Elliott LLP
  • Canada
  • April 22 2010

After almost one year of public consultation, the revised draft of the City of Toronto's proposed zoning by-law has been released for public review and comment.


Eli Lilly-Apotex patent litigation comes to an end
  • Stikeman Elliott LLP
  • Canada
  • April 21 2010

On October 1, 2009, the Federal Court of Canada, in Eli Lilly and Company v. Apotex Inc., rejected a counterclaim by Apotex, a generic pharmaceutical manufacturer, in which it had sought damages pursuant to section 36 of the Competition Act (the "Act") against two brand name pharmaceutical manufacturers in connection with a patent assignment.


Court of Appeal for Ontario reformulates the test for assuming jurisdiction over foreign defendants - Van Breda v. Village Resorts Ltd
  • Stikeman Elliott LLP
  • Canada
  • March 25 2010

A special five-member panel of the Court of Appeal for Ontario recently released its judgment in Van Breda v. Village Resorts Ltd.


Proof of loss by proof of gain: B.C. Court of Appeal reversal certifies DRAM price-fixing class action
  • Stikeman Elliott LLP
  • Canada
  • November 19 2009

On November 12, 2009, the British Columbia Court of Appeal unanimously allowed an appeal from the dismissal of a class certification motion in an action alleging price-fixing against certain manufacturers of DRAM (dynamic random access memory) chips, which are found in a wide variety of electronics products.


OSC declines application to overturn TSX decision allowing private placement without unitholder approval
  • Stikeman Elliott LLP
  • Canada
  • August 28 2009

On August 26, the Ontario Securities Commission released a decision refusing to intervene in a case where the TSX allowed a private placement of units of a real estate investment trust without unitholder approval.


Ontario Superior Court of Justice rejects bank-overtime class action certification
  • Stikeman Elliott LLP
  • Canada
  • July 21 2009

In the recent decision in Fresco v. CIBC, Justice Lax of the Ontario Superior Court of Justice dismissed a certification motion by a representative plaintiff seeking compensation for unpaid overtime allegedly caused by CIBC's overtime policies.